LifeMD (NASDAQ:LFMD) Stock Rating Reaffirmed by HC Wainwright

LifeMD (NASDAQ:LFMD - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 28.76% from the stock's previous close.

A number of other research analysts also recently weighed in on LFMD. Cantor Fitzgerald upped their price objective on shares of LifeMD from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday. BTIG Research upped their price target on shares of LifeMD from $13.00 to $14.00 and gave the stock a "buy" rating in a research report on Tuesday, April 23rd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, LifeMD currently has an average rating of "Buy" and a consensus price target of $11.60.

LifeMD Stock Up 0.2 %

NASDAQ:LFMD traded up $0.02 during trading hours on Friday, reaching $9.32. The company's stock had a trading volume of 1,406,366 shares, compared to its average volume of 845,345. The company has a market capitalization of $381.09 million, a P/E ratio of -13.57 and a beta of 1.38. LifeMD has a 12 month low of $1.66 and a 12 month high of $12.88. The company has a debt-to-equity ratio of 3.22, a quick ratio of 1.15 and a current ratio of 1.22. The stock has a 50 day moving average price of $10.21 and a two-hundred day moving average price of $8.09.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The business had revenue of $44.86 million during the quarter, compared to the consensus estimate of $40.65 million. Equities analysts predict that LifeMD will post -0.14 EPS for the current fiscal year.

Institutional Trading of LifeMD

Large investors have recently bought and sold shares of the business. Barclays PLC purchased a new stake in LifeMD during the 3rd quarter valued at about $142,000. Citigroup Inc. purchased a new stake in LifeMD during the 3rd quarter valued at about $266,000. Raymond James Financial Services Advisors Inc. purchased a new stake in LifeMD during the 4th quarter valued at about $173,000. Jump Financial LLC purchased a new stake in LifeMD during the 3rd quarter valued at about $465,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in LifeMD during the 3rd quarter valued at about $577,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.